Ireland says ash will not close airports

birou notarial

DUBLIN | Tue May 24, 2011 3:49am EDT

"All Irish airports remain open but some services may be affected by restrictions imposed by other European service providers," the IAA said on its website.

Irish airlines Ryanair (RYA.I) and Aer Lingus (AERL.I) have had to cancel dozens of flights in and out of Scotland on Tuesday due to the volcanic ash.

Birou Notarial Bucuresti

Baloane

DUBLIN | Tue May 24, 2011 3:49am EDT

"All Irish airports remain open but some services may be affected by restrictions imposed by other European service providers," the IAA said on its website.

Irish airlines Ryanair (RYA.I) and Aer Lingus (AERL.I) have had to cancel dozens of flights in and out of Scotland on Tuesday due to the volcanic ash.

Baloane

Cost aparat dentar

DUBLIN | Tue May 24, 2011 3:49am EDT

"All Irish airports remain open but some services may be affected by restrictions imposed by other European service providers," the IAA said on its website.

Irish airlines Ryanair (RYA.I) and Aer Lingus (AERL.I) have had to cancel dozens of flights in and out of Scotland on Tuesday due to the volcanic ash.

Cost aparat dentar

UPDATE 2-AstraZeneca gets Japan boost with cancer drug deal

birou notarial

* To co-promote Amgen's denosumab for cancer with Daiichi

* AstraZeneca seeking to build presence in Japan

* Global denosumab sales seen $3.3 bln by 2015 - consensus

(Adds background on drug, AstraZeneca in Japan)

By Ben Hirschler

LONDON, May 24 (Reuters) - AstraZeneca (AZN.L) is to co-promote Amgen's (AMGN.O) promising new drug denosumab in Japan as a treatment for bone cancer disorders alongside Daiichi Sankyo (4568.T), boosting its presence in the country.

Japan is a growing focus for Western drugmakers, who see good prospects in the country as more medicines originally developed for U.S. and European markets are introduced.

Daiichi acquired rights to denosumab from Amgen in 2007 and filed an application for marketing authorisation last year. The injectable drug is currently awaiting approval from Japanese authorities.

Financial terms of the agreement between AstraZeneca and Daiichi, announced on Tuesday, were not disclosed.

Denosumab is the first in a new class of medicines that work by blocking a protein that activates bone-destroying cells called osteoclasts. It is viewed as a critical growth driver for U.S. biotech company Amgen.

Analysts, on average, have forecast annual denosumab sales of $3.3 billion by 2015, according to Thomson Reuters Pharma.

In order to maximise sales, Amgen has decided to strike regional development and marketing deals with other big drug companies. In addition to the tie-up with Daiichi, Amgen also has a deal with GlaxoSmithKline (GSK.L) covering Europe and several big emerging markets.

Denosumab is currently approved in the United States and Europe, under the trade name Xgeva, as a treatment for reducing fractures and other bone problems in certain cancer patients. It is also sold under the brand name Prolia for osteoporosis.

Tony Zook, the head of AstraZeneca's global commercial organisation, said the co-promotion deal with Daiichi would leverage the Anglo-Swedish company's strong position in cancer.

The deal does not include the osteoporosis indication, for which Daiichi also has marketing rights in Japan.

Japan is AstraZeneca's second largest market globally and a growing focus for the drugmaker, which generated revenue of $2.6 billion in the country last year, up 4 percent on 2009.

AstraZeneca already sells cholesterol fighter Crestor, Losec for stomach acid, asthma drug Symbicort and several cancer treatments in Japan. It expects to launch Nexium, the follow-on to Losec, within the next 12 months.

Birou Notarial Bucuresti

Baloane

* To co-promote Amgen's denosumab for cancer with Daiichi

* AstraZeneca seeking to build presence in Japan

* Global denosumab sales seen $3.3 bln by 2015 - consensus

(Adds background on drug, AstraZeneca in Japan)

By Ben Hirschler

LONDON, May 24 (Reuters) - AstraZeneca (AZN.L) is to co-promote Amgen's (AMGN.O) promising new drug denosumab in Japan as a treatment for bone cancer disorders alongside Daiichi Sankyo (4568.T), boosting its presence in the country.

Japan is a growing focus for Western drugmakers, who see good prospects in the country as more medicines originally developed for U.S. and European markets are introduced.

Daiichi acquired rights to denosumab from Amgen in 2007 and filed an application for marketing authorisation last year. The injectable drug is currently awaiting approval from Japanese authorities.

Financial terms of the agreement between AstraZeneca and Daiichi, announced on Tuesday, were not disclosed.

Denosumab is the first in a new class of medicines that work by blocking a protein that activates bone-destroying cells called osteoclasts. It is viewed as a critical growth driver for U.S. biotech company Amgen.

Analysts, on average, have forecast annual denosumab sales of $3.3 billion by 2015, according to Thomson Reuters Pharma.

In order to maximise sales, Amgen has decided to strike regional development and marketing deals with other big drug companies. In addition to the tie-up with Daiichi, Amgen also has a deal with GlaxoSmithKline (GSK.L) covering Europe and several big emerging markets.

Denosumab is currently approved in the United States and Europe, under the trade name Xgeva, as a treatment for reducing fractures and other bone problems in certain cancer patients. It is also sold under the brand name Prolia for osteoporosis.

Tony Zook, the head of AstraZeneca's global commercial organisation, said the co-promotion deal with Daiichi would leverage the Anglo-Swedish company's strong position in cancer.

The deal does not include the osteoporosis indication, for which Daiichi also has marketing rights in Japan.

Japan is AstraZeneca's second largest market globally and a growing focus for the drugmaker, which generated revenue of $2.6 billion in the country last year, up 4 percent on 2009.

AstraZeneca already sells cholesterol fighter Crestor, Losec for stomach acid, asthma drug Symbicort and several cancer treatments in Japan. It expects to launch Nexium, the follow-on to Losec, within the next 12 months.

Baloane

Cost aparat dentar

* To co-promote Amgen's denosumab for cancer with Daiichi

* AstraZeneca seeking to build presence in Japan

* Global denosumab sales seen $3.3 bln by 2015 - consensus

(Adds background on drug, AstraZeneca in Japan)

By Ben Hirschler

LONDON, May 24 (Reuters) - AstraZeneca (AZN.L) is to co-promote Amgen's (AMGN.O) promising new drug denosumab in Japan as a treatment for bone cancer disorders alongside Daiichi Sankyo (4568.T), boosting its presence in the country.

Japan is a growing focus for Western drugmakers, who see good prospects in the country as more medicines originally developed for U.S. and European markets are introduced.

Daiichi acquired rights to denosumab from Amgen in 2007 and filed an application for marketing authorisation last year. The injectable drug is currently awaiting approval from Japanese authorities.

Financial terms of the agreement between AstraZeneca and Daiichi, announced on Tuesday, were not disclosed.

Denosumab is the first in a new class of medicines that work by blocking a protein that activates bone-destroying cells called osteoclasts. It is viewed as a critical growth driver for U.S. biotech company Amgen.

Analysts, on average, have forecast annual denosumab sales of $3.3 billion by 2015, according to Thomson Reuters Pharma.

In order to maximise sales, Amgen has decided to strike regional development and marketing deals with other big drug companies. In addition to the tie-up with Daiichi, Amgen also has a deal with GlaxoSmithKline (GSK.L) covering Europe and several big emerging markets.

Denosumab is currently approved in the United States and Europe, under the trade name Xgeva, as a treatment for reducing fractures and other bone problems in certain cancer patients. It is also sold under the brand name Prolia for osteoporosis.

Tony Zook, the head of AstraZeneca's global commercial organisation, said the co-promotion deal with Daiichi would leverage the Anglo-Swedish company's strong position in cancer.

The deal does not include the osteoporosis indication, for which Daiichi also has marketing rights in Japan.

Japan is AstraZeneca's second largest market globally and a growing focus for the drugmaker, which generated revenue of $2.6 billion in the country last year, up 4 percent on 2009.

AstraZeneca already sells cholesterol fighter Crestor, Losec for stomach acid, asthma drug Symbicort and several cancer treatments in Japan. It expects to launch Nexium, the follow-on to Losec, within the next 12 months.

Cost aparat dentar

Morgan Stanley fund to invest $200 mln in India road JV with Spain co

birou notarial

MUMBAI | Tue May 24, 2011 4:00am EDT

MUMBAI May 24 (Reuters) - Morgan Stanley's global infrastructure fund will invest up to $200 million in a joint venture with a unit of Spain's Grupo Isolux Corsan, which holds rights to build three highway projects in India, the two firms said on Tuesday.

Isolux Corsan will bring in an equal investment in the venture through the unit.

The JV holds long-term rights for three projects to build over 400 kilometres of highways in western and northern India, with total cost estimated at $1.6 billion.

India has targeted doubling in infrastructure spending to $1 trillion in the five years starting in 2012, as Asia's third largest economy looks to boost growth.

The government has focused on a $50 billion road building programme, but foreign investors have shied away from the sector due to problems in land acquisition and a slow adoption of the toll-road model in India.

"The joint venture adds to our successful presence in India's transportation sector, providing us with an excellent road concession platform in a market that is experiencing rapid urbanization and dramatic growth in vehicles," said Gautam Bhandari, head of Morgan Stanley Infrastructure Asia.

The JV's projects, which involve expansion of existing roads, have already received commitments for the debt component, while Isolux Corsán has made substantial equity investment. (Reporting by Prashant Mehra and Sumeet Chatterjee; Editing by Aradhana Aravindan)

Birou Notarial Bucuresti

Baloane

MUMBAI | Tue May 24, 2011 4:00am EDT

MUMBAI May 24 (Reuters) - Morgan Stanley's global infrastructure fund will invest up to $200 million in a joint venture with a unit of Spain's Grupo Isolux Corsan, which holds rights to build three highway projects in India, the two firms said on Tuesday.

Isolux Corsan will bring in an equal investment in the venture through the unit.

The JV holds long-term rights for three projects to build over 400 kilometres of highways in western and northern India, with total cost estimated at $1.6 billion.

India has targeted doubling in infrastructure spending to $1 trillion in the five years starting in 2012, as Asia's third largest economy looks to boost growth.

The government has focused on a $50 billion road building programme, but foreign investors have shied away from the sector due to problems in land acquisition and a slow adoption of the toll-road model in India.

"The joint venture adds to our successful presence in India's transportation sector, providing us with an excellent road concession platform in a market that is experiencing rapid urbanization and dramatic growth in vehicles," said Gautam Bhandari, head of Morgan Stanley Infrastructure Asia.

The JV's projects, which involve expansion of existing roads, have already received commitments for the debt component, while Isolux Corsán has made substantial equity investment. (Reporting by Prashant Mehra and Sumeet Chatterjee; Editing by Aradhana Aravindan)

Baloane

Cost aparat dentar

MUMBAI | Tue May 24, 2011 4:00am EDT

MUMBAI May 24 (Reuters) - Morgan Stanley's global infrastructure fund will invest up to $200 million in a joint venture with a unit of Spain's Grupo Isolux Corsan, which holds rights to build three highway projects in India, the two firms said on Tuesday.

Isolux Corsan will bring in an equal investment in the venture through the unit.

The JV holds long-term rights for three projects to build over 400 kilometres of highways in western and northern India, with total cost estimated at $1.6 billion.

India has targeted doubling in infrastructure spending to $1 trillion in the five years starting in 2012, as Asia's third largest economy looks to boost growth.

The government has focused on a $50 billion road building programme, but foreign investors have shied away from the sector due to problems in land acquisition and a slow adoption of the toll-road model in India.

"The joint venture adds to our successful presence in India's transportation sector, providing us with an excellent road concession platform in a market that is experiencing rapid urbanization and dramatic growth in vehicles," said Gautam Bhandari, head of Morgan Stanley Infrastructure Asia.

The JV's projects, which involve expansion of existing roads, have already received commitments for the debt component, while Isolux Corsán has made substantial equity investment. (Reporting by Prashant Mehra and Sumeet Chatterjee; Editing by Aradhana Aravindan)

Cost aparat dentar

REFILE-UPDATE 1-Goldman Sachs raises 2011, 2012 Brent crude price forecast

birou notarial

(Fixes typo in third paragraph)

* Goldman raises yr-end Brent forecast to $120/bbl from $105

* Recommends buying Brent Dec 2012 contract

* Only matter of time before OPEC spare capacity exhausted (Adds outlook on metals, details)

SINGAPORE, May 24 (Reuters) - Goldman Sachs has raised its Brent crude price forecast for 2011 and 2012 on expectations that fuel demand growth will draw on global inventories and strain OPEC's spare oil output capacity.

The Wall Street bank said it was "structurally bullish" on oil and raised its year-end Brent forecast to $120 per barrel from $105 a barrel, and its 2012 forecast to $140 from $120.

"It is only a matter of time until inventories and OPEC spare capacity will become effectively exhausted, requiring higher oil prices to restrain demand, keeping it in line with available supplies," Goldman analysts led by David Greely said in a report dated Monday.

Goldman predicted in April a correction in oil prices, ahead of the asset-wide rout earlier this month. It said the recent pull back provides a good entry point to buy oil and recommended going long on the December 2012 ICE Brent crude contract.

"We expect that the ongoing loss of Libyan production and disappointing non-OPEC production will continue to tighten the oil market to critically tight levels in early 2012," the report said.

Goldman also said that the current pause in economic growth is nearing a trough and creating upside potential for metal prices.

"While a sharp decline in world economic growth remains a downside risk to commodity prices, we see the current slowdown in economic growth as part of a normal mid-cycle pause, partially driven by higher commodity prices, and therefore not a reason to expect commodity prices to decline substantially," the report said. (Reporting by Francis Kan; Editing by Manash Goswami)

Birou Notarial Bucuresti

Baloane

(Fixes typo in third paragraph)

* Goldman raises yr-end Brent forecast to $120/bbl from $105

* Recommends buying Brent Dec 2012 contract

* Only matter of time before OPEC spare capacity exhausted (Adds outlook on metals, details)

SINGAPORE, May 24 (Reuters) - Goldman Sachs has raised its Brent crude price forecast for 2011 and 2012 on expectations that fuel demand growth will draw on global inventories and strain OPEC's spare oil output capacity.

The Wall Street bank said it was "structurally bullish" on oil and raised its year-end Brent forecast to $120 per barrel from $105 a barrel, and its 2012 forecast to $140 from $120.

"It is only a matter of time until inventories and OPEC spare capacity will become effectively exhausted, requiring higher oil prices to restrain demand, keeping it in line with available supplies," Goldman analysts led by David Greely said in a report dated Monday.

Goldman predicted in April a correction in oil prices, ahead of the asset-wide rout earlier this month. It said the recent pull back provides a good entry point to buy oil and recommended going long on the December 2012 ICE Brent crude contract.

"We expect that the ongoing loss of Libyan production and disappointing non-OPEC production will continue to tighten the oil market to critically tight levels in early 2012," the report said.

Goldman also said that the current pause in economic growth is nearing a trough and creating upside potential for metal prices.

"While a sharp decline in world economic growth remains a downside risk to commodity prices, we see the current slowdown in economic growth as part of a normal mid-cycle pause, partially driven by higher commodity prices, and therefore not a reason to expect commodity prices to decline substantially," the report said. (Reporting by Francis Kan; Editing by Manash Goswami)

Baloane

Cost aparat dentar

(Fixes typo in third paragraph)

* Goldman raises yr-end Brent forecast to $120/bbl from $105

* Recommends buying Brent Dec 2012 contract

* Only matter of time before OPEC spare capacity exhausted (Adds outlook on metals, details)

SINGAPORE, May 24 (Reuters) - Goldman Sachs has raised its Brent crude price forecast for 2011 and 2012 on expectations that fuel demand growth will draw on global inventories and strain OPEC's spare oil output capacity.

The Wall Street bank said it was "structurally bullish" on oil and raised its year-end Brent forecast to $120 per barrel from $105 a barrel, and its 2012 forecast to $140 from $120.

"It is only a matter of time until inventories and OPEC spare capacity will become effectively exhausted, requiring higher oil prices to restrain demand, keeping it in line with available supplies," Goldman analysts led by David Greely said in a report dated Monday.

Goldman predicted in April a correction in oil prices, ahead of the asset-wide rout earlier this month. It said the recent pull back provides a good entry point to buy oil and recommended going long on the December 2012 ICE Brent crude contract.

"We expect that the ongoing loss of Libyan production and disappointing non-OPEC production will continue to tighten the oil market to critically tight levels in early 2012," the report said.

Goldman also said that the current pause in economic growth is nearing a trough and creating upside potential for metal prices.

"While a sharp decline in world economic growth remains a downside risk to commodity prices, we see the current slowdown in economic growth as part of a normal mid-cycle pause, partially driven by higher commodity prices, and therefore not a reason to expect commodity prices to decline substantially," the report said. (Reporting by Francis Kan; Editing by Manash Goswami)

Cost aparat dentar

UPDATE 4-Sony sees 2010/11 net loss of $3.2 bln on tax write-offs

birou notarial

* Sony cuts net estimate to 260 bln yen loss vs 70 bln profit previous

* Leaves operating profit forecast at 200 bln yen

* Analysts' forecast operating profit of 197 bln yen

* Sony sees 2011/12 operating profit at same level as 2010/2011

* Shares end down 0.5 pct ahead of announcement (Adds set of links)

TOKYO, May 23 (Reuters) - Sony Corp said on Monday it would post a $3.2 billion net loss for the year that ended on March 31, the latest setback for the Japanese consumer electronics giant.

The maker of the PlayStation video games, Vaio computers and Trinitron TVs has been battling to recover from the devastating earthquake in March, and more recently, a series of computing hacking attacks.

It is due to announce its full-year earnings on Thursday.

Sony said it now expected a net loss of 260 billion yen ($3.2 billion) versus a previous forecast for a profit of 70 billion yen, thanks to a "non-cash charge" of around 360 billion yen related to Japanese tax credits.

The company stuck with its earlier forecast, issued before the March 11 earthquake, for an annual operating profit of 200 billion yen ($2.4 billion).

In its first estimate for the year to March 2012, Sony said its operating profit would also be around 200 billion yen.

The devastating earthquake and tsunami in March damaged Sony plants in northeastern Japan, snarled the supply chain and triggered a plunge in domestic consumption.

Sony estimated the impact of the quake in the current year at 150 billion yen at the operating level.

Regarding the hacking attacks that forced the company to shutdown its PlayStation Network, Sony said "known costs" were estimated at 14 billion yen. Sony is targeting the end of May for fully restoring the affected networks.

Many rival corporations, including Panasonic Corp , have yet to issue forecasts for the current financial year to March 2012, due to uncertainty following the disaster.

An analysts' consensus, according to a SmartEstimates by Thomson Reuters I/B/E/S, is for a 2010/2011 operating profit of 197 billion yen. SmartEstimates place more weight on recent estimates by highly rated analysts.

($1 = 81.710 Japanese Yen) (Reporting by Isabel Reynolds; Editing by Lincoln Feast)

Birou Notarial Bucuresti

Baloane

* Sony cuts net estimate to 260 bln yen loss vs 70 bln profit previous

* Leaves operating profit forecast at 200 bln yen

* Analysts' forecast operating profit of 197 bln yen

* Sony sees 2011/12 operating profit at same level as 2010/2011

* Shares end down 0.5 pct ahead of announcement (Adds set of links)

TOKYO, May 23 (Reuters) - Sony Corp said on Monday it would post a $3.2 billion net loss for the year that ended on March 31, the latest setback for the Japanese consumer electronics giant.

The maker of the PlayStation video games, Vaio computers and Trinitron TVs has been battling to recover from the devastating earthquake in March, and more recently, a series of computing hacking attacks.

It is due to announce its full-year earnings on Thursday.

Sony said it now expected a net loss of 260 billion yen ($3.2 billion) versus a previous forecast for a profit of 70 billion yen, thanks to a "non-cash charge" of around 360 billion yen related to Japanese tax credits.

The company stuck with its earlier forecast, issued before the March 11 earthquake, for an annual operating profit of 200 billion yen ($2.4 billion).

In its first estimate for the year to March 2012, Sony said its operating profit would also be around 200 billion yen.

The devastating earthquake and tsunami in March damaged Sony plants in northeastern Japan, snarled the supply chain and triggered a plunge in domestic consumption.

Sony estimated the impact of the quake in the current year at 150 billion yen at the operating level.

Regarding the hacking attacks that forced the company to shutdown its PlayStation Network, Sony said "known costs" were estimated at 14 billion yen. Sony is targeting the end of May for fully restoring the affected networks.

Many rival corporations, including Panasonic Corp , have yet to issue forecasts for the current financial year to March 2012, due to uncertainty following the disaster.

An analysts' consensus, according to a SmartEstimates by Thomson Reuters I/B/E/S, is for a 2010/2011 operating profit of 197 billion yen. SmartEstimates place more weight on recent estimates by highly rated analysts.

($1 = 81.710 Japanese Yen) (Reporting by Isabel Reynolds; Editing by Lincoln Feast)

Baloane

Cost aparat dentar

* Sony cuts net estimate to 260 bln yen loss vs 70 bln profit previous

* Leaves operating profit forecast at 200 bln yen

* Analysts' forecast operating profit of 197 bln yen

* Sony sees 2011/12 operating profit at same level as 2010/2011

* Shares end down 0.5 pct ahead of announcement (Adds set of links)

TOKYO, May 23 (Reuters) - Sony Corp said on Monday it would post a $3.2 billion net loss for the year that ended on March 31, the latest setback for the Japanese consumer electronics giant.

The maker of the PlayStation video games, Vaio computers and Trinitron TVs has been battling to recover from the devastating earthquake in March, and more recently, a series of computing hacking attacks.

It is due to announce its full-year earnings on Thursday.

Sony said it now expected a net loss of 260 billion yen ($3.2 billion) versus a previous forecast for a profit of 70 billion yen, thanks to a "non-cash charge" of around 360 billion yen related to Japanese tax credits.

The company stuck with its earlier forecast, issued before the March 11 earthquake, for an annual operating profit of 200 billion yen ($2.4 billion).

In its first estimate for the year to March 2012, Sony said its operating profit would also be around 200 billion yen.

The devastating earthquake and tsunami in March damaged Sony plants in northeastern Japan, snarled the supply chain and triggered a plunge in domestic consumption.

Sony estimated the impact of the quake in the current year at 150 billion yen at the operating level.

Regarding the hacking attacks that forced the company to shutdown its PlayStation Network, Sony said "known costs" were estimated at 14 billion yen. Sony is targeting the end of May for fully restoring the affected networks.

Many rival corporations, including Panasonic Corp , have yet to issue forecasts for the current financial year to March 2012, due to uncertainty following the disaster.

An analysts' consensus, according to a SmartEstimates by Thomson Reuters I/B/E/S, is for a 2010/2011 operating profit of 197 billion yen. SmartEstimates place more weight on recent estimates by highly rated analysts.

($1 = 81.710 Japanese Yen) (Reporting by Isabel Reynolds; Editing by Lincoln Feast)

Cost aparat dentar

UPDATE 1-Dutch chemical sector Q1 sales up, industry optimistic

birou notarial

* Dutch chemical sector sales rise 22 pct year-on-year

* Companies confident risks are manageable -group

(Adds details)

AMSTERDAM, May 23 (Reuters) - Dutch chemical sector sales grew 22 percent in the first quarter and companies are looking to increase investments in 2011 on the assumption that market uncertainties will be manageable, an industry body said.

The Dutch Chemical Industry Association (VNCI) said on Monday the sector was continuing its recovery, with quarterly sales growth coming from increased production and higher selling prices as companies passed on rising costs to customers.

Output rose by almost 3 percent in the first quarter, VNCI said, pointing to Statistics Netherlands figures.

"Chemical companies are generally optimistic and see both opportunities and causes for concern for the remainder of the year," VNCI said in a statement.

VNCI, whose members include Dutch paints group AkzoNobel (AKZO.AS) and vitamins maker DSM (DSMN.AS), pointed to Statistics Netherlands figures indicating businesses in the industry plan to increase investment by 73 percent in 2011.

This compares with a 36 percent drop in investments in 2010 to 0.9 billion euros from 1.4 billion in 2009.

The planned investments show a mixed picture, however, as companies are keen to spend on R&D and efficiency improvements but also deferred expansion investments.

VNCI Chairman Werner Fuhrmann said it was uncertain whether 2011 would be a better year for the sector than 2010 as this was dependent on the euro crisis, the after-effects of the Japanese earthquake, inflation in China and turmoil in the Middle East.

The chemical industry is primarily oriented at exports, which makes it very sensitive to such developments, currency rate movements and fluctuating oil and raw-material prices.

Global chemicals companies have been battling rising raw materials costs. AkzoNobel and DSM reported strong quarterly results on improved demand and price hikes as they also guided for improved results in 2011. [ID:nLDE63L2KS] [ID:nLDE71L06B]

In 2010, chemical industry production rose by more than 7 percent in 2010, while sales rose by 25 percent to 47 billion euro ($66.1 billion), while selling prices rose by 20 percent. (Reporting by Aaron Gray-Block; Editing by Hans Peters) ($1=.7109 Euro)

Birou Notarial Bucuresti

Baloane

* Dutch chemical sector sales rise 22 pct year-on-year

* Companies confident risks are manageable -group

(Adds details)

AMSTERDAM, May 23 (Reuters) - Dutch chemical sector sales grew 22 percent in the first quarter and companies are looking to increase investments in 2011 on the assumption that market uncertainties will be manageable, an industry body said.

The Dutch Chemical Industry Association (VNCI) said on Monday the sector was continuing its recovery, with quarterly sales growth coming from increased production and higher selling prices as companies passed on rising costs to customers.

Output rose by almost 3 percent in the first quarter, VNCI said, pointing to Statistics Netherlands figures.

"Chemical companies are generally optimistic and see both opportunities and causes for concern for the remainder of the year," VNCI said in a statement.

VNCI, whose members include Dutch paints group AkzoNobel (AKZO.AS) and vitamins maker DSM (DSMN.AS), pointed to Statistics Netherlands figures indicating businesses in the industry plan to increase investment by 73 percent in 2011.

This compares with a 36 percent drop in investments in 2010 to 0.9 billion euros from 1.4 billion in 2009.

The planned investments show a mixed picture, however, as companies are keen to spend on R&D and efficiency improvements but also deferred expansion investments.

VNCI Chairman Werner Fuhrmann said it was uncertain whether 2011 would be a better year for the sector than 2010 as this was dependent on the euro crisis, the after-effects of the Japanese earthquake, inflation in China and turmoil in the Middle East.

The chemical industry is primarily oriented at exports, which makes it very sensitive to such developments, currency rate movements and fluctuating oil and raw-material prices.

Global chemicals companies have been battling rising raw materials costs. AkzoNobel and DSM reported strong quarterly results on improved demand and price hikes as they also guided for improved results in 2011. [ID:nLDE63L2KS] [ID:nLDE71L06B]

In 2010, chemical industry production rose by more than 7 percent in 2010, while sales rose by 25 percent to 47 billion euro ($66.1 billion), while selling prices rose by 20 percent. (Reporting by Aaron Gray-Block; Editing by Hans Peters) ($1=.7109 Euro)

Baloane

Cost aparat dentar

* Dutch chemical sector sales rise 22 pct year-on-year

* Companies confident risks are manageable -group

(Adds details)

AMSTERDAM, May 23 (Reuters) - Dutch chemical sector sales grew 22 percent in the first quarter and companies are looking to increase investments in 2011 on the assumption that market uncertainties will be manageable, an industry body said.

The Dutch Chemical Industry Association (VNCI) said on Monday the sector was continuing its recovery, with quarterly sales growth coming from increased production and higher selling prices as companies passed on rising costs to customers.

Output rose by almost 3 percent in the first quarter, VNCI said, pointing to Statistics Netherlands figures.

"Chemical companies are generally optimistic and see both opportunities and causes for concern for the remainder of the year," VNCI said in a statement.

VNCI, whose members include Dutch paints group AkzoNobel (AKZO.AS) and vitamins maker DSM (DSMN.AS), pointed to Statistics Netherlands figures indicating businesses in the industry plan to increase investment by 73 percent in 2011.

This compares with a 36 percent drop in investments in 2010 to 0.9 billion euros from 1.4 billion in 2009.

The planned investments show a mixed picture, however, as companies are keen to spend on R&D and efficiency improvements but also deferred expansion investments.

VNCI Chairman Werner Fuhrmann said it was uncertain whether 2011 would be a better year for the sector than 2010 as this was dependent on the euro crisis, the after-effects of the Japanese earthquake, inflation in China and turmoil in the Middle East.

The chemical industry is primarily oriented at exports, which makes it very sensitive to such developments, currency rate movements and fluctuating oil and raw-material prices.

Global chemicals companies have been battling rising raw materials costs. AkzoNobel and DSM reported strong quarterly results on improved demand and price hikes as they also guided for improved results in 2011. [ID:nLDE63L2KS] [ID:nLDE71L06B]

In 2010, chemical industry production rose by more than 7 percent in 2010, while sales rose by 25 percent to 47 billion euro ($66.1 billion), while selling prices rose by 20 percent. (Reporting by Aaron Gray-Block; Editing by Hans Peters) ($1=.7109 Euro)

Cost aparat dentar

UPDATE 1-P&G plans to invest $100 mln in Indonesia oleochemicals

birou notarial

(Adds quotes, background)

JAKARTA May 23 (Reuters) - Procter & Gamble Co (P&G) will invest $100 million in the oleochemical sector in Indonesia, the country's industry minister MS Hidayat said on Monday.

"P&G is anticipating the need for 200,000 tonnes of fatty alcohol in the coming ten years from Indonesia," Hidayat said following a meeting with P&G officials at his office.

"To meet the need they are preparing at least $100 million to set up a joint venture with the local partner in the sector," Hidayat added.

High commodity prices and government efforts to boost downstream industries have started to attract investment in Indonesia over the past year.

Indonesia plans to offer fiscal incentives and restructure its export tax policy on crude palm oil, after it steadily hiked the tax to 25 percent in February from just 3 percent a year ago, to do more to spur downstream processing in the country.

The country is still reliant on exports of raw materials, and is aiming to move up the value chain.

Agriculture companies are looking to take advantage of growing wealth within Southeast Asia's biggest economy.

Indonesia's economy grew by 6.5 percent in the first quarter of 2011 from a year earlier, data showed in early May, due in part to strong domestic consumption. (Reporting by Yayat Supriatna; Writing by Michael Taylor; Editing by Muralikumar Anantharaman)

Birou Notarial Bucuresti

Baloane

(Adds quotes, background)

JAKARTA May 23 (Reuters) - Procter & Gamble Co (P&G) will invest $100 million in the oleochemical sector in Indonesia, the country's industry minister MS Hidayat said on Monday.

"P&G is anticipating the need for 200,000 tonnes of fatty alcohol in the coming ten years from Indonesia," Hidayat said following a meeting with P&G officials at his office.

"To meet the need they are preparing at least $100 million to set up a joint venture with the local partner in the sector," Hidayat added.

High commodity prices and government efforts to boost downstream industries have started to attract investment in Indonesia over the past year.

Indonesia plans to offer fiscal incentives and restructure its export tax policy on crude palm oil, after it steadily hiked the tax to 25 percent in February from just 3 percent a year ago, to do more to spur downstream processing in the country.

The country is still reliant on exports of raw materials, and is aiming to move up the value chain.

Agriculture companies are looking to take advantage of growing wealth within Southeast Asia's biggest economy.

Indonesia's economy grew by 6.5 percent in the first quarter of 2011 from a year earlier, data showed in early May, due in part to strong domestic consumption. (Reporting by Yayat Supriatna; Writing by Michael Taylor; Editing by Muralikumar Anantharaman)

Baloane

Cost aparat dentar

(Adds quotes, background)

JAKARTA May 23 (Reuters) - Procter & Gamble Co (P&G) will invest $100 million in the oleochemical sector in Indonesia, the country's industry minister MS Hidayat said on Monday.

"P&G is anticipating the need for 200,000 tonnes of fatty alcohol in the coming ten years from Indonesia," Hidayat said following a meeting with P&G officials at his office.

"To meet the need they are preparing at least $100 million to set up a joint venture with the local partner in the sector," Hidayat added.

High commodity prices and government efforts to boost downstream industries have started to attract investment in Indonesia over the past year.

Indonesia plans to offer fiscal incentives and restructure its export tax policy on crude palm oil, after it steadily hiked the tax to 25 percent in February from just 3 percent a year ago, to do more to spur downstream processing in the country.

The country is still reliant on exports of raw materials, and is aiming to move up the value chain.

Agriculture companies are looking to take advantage of growing wealth within Southeast Asia's biggest economy.

Indonesia's economy grew by 6.5 percent in the first quarter of 2011 from a year earlier, data showed in early May, due in part to strong domestic consumption. (Reporting by Yayat Supriatna; Writing by Michael Taylor; Editing by Muralikumar Anantharaman)

Cost aparat dentar